Taisho Pharmaceutical Holdings Co., Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TAIPY research report →
Companywww.taisho-holdings.co.jp
Taisho Pharmaceutical Holdings Co. , Ltd. , through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally.
- CEO
- Akira Uehara
- IPO
- 2021
- Employees
- 8,784
- HQ
- Tokyo, JP
Price Chart
Valuation
- Market Cap
- $18.13B
- P/E
- 37.03
- P/S
- 2.33
- P/B
- 0.89
- EV/EBITDA
- 8.27
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 59.01%
- Op Margin
- 7.64%
- Net Margin
- 6.30%
- ROE
- 2.48%
- ROIC
- 1.91%
Growth & Income
- Revenue
- $301.38B · 12.37%
- Net Income
- $19.00B · 44.77%
- EPS
- $231.73 · 43.82%
- Op Income
- $23.02B
- FCF YoY
- -166.64%
Performance & Tape
- 52W High
- $15.52
- 52W Low
- $8.88
- 50D MA
- $12.20
- 200D MA
- $12.93
- Beta
- 0.44
- Avg Volume
- 202
Get TickerSpark's AI analysis on TAIPY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our TAIPY Coverage
We haven't published any research on TAIPY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TAIPY Report →